Congress seeks Medicare coverage for FDA-reviewed blood tests that screen for Alzheimer’s early, starting in 2028
A senate committee must act next: committee consideration.
No action since November 2025
How this policy affects specific groups of people
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Advocacy group reaction to the introduction of the ASAP Act, describing how it would create a Medicare pathway for FDA-cleared/approved blood-based dementia screening tests.
AIM statement applauding the bipartisan introduction of the ASAP Act and emphasizing Medicare coverage pathways for FDA-reviewed blood biomarker screening tests.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
ASAP Act
Analysis generated by AI. Always verify with official sources.